Peptide Research Resources & Further Reading
Last updated July 2, 2026 · Medically reviewed by David Chen, MD, PhD
Going deeper on GLP-1 peptides means reading widely — primary trial data, reference summaries, and the official drug labels. Below is a curated starting set: reference wikis for orientation, the databases where the actual evidence lives, our own interactive tools, and the clinical studies we draw on throughout this site.
Reference & wikis
- GLP-1 receptor agonist — WikipediaOverview of the drug class, mechanism, and history.
- Semaglutide — WikipediaPharmacology, trials, and approvals for semaglutide.
- Tirzepatide — WikipediaReference page for the GLP-1 + GIP dual agonist.
- Retatrutide — WikipediaReference page for the triple agonist in trials.
Clinical databases
- PubMedSearch the primary biomedical literature for any compound or trial.
- ClinicalTrials.govRegistry of clinical studies — find the STEP, SURMOUNT, and TRIUMPH trials directly.
- DailyMedOfficial FDA drug labels and prescribing information.
Interactive tools
- Dosing calculatorProject weight loss and build a titration schedule by compound and dose.
- Reconstitution calculatorConvert a milligram dose to units on the syringe at any concentration.
- Compound comparisonSemaglutide, tirzepatide, and retatrutide side by side.
Key clinical studies
The trials behind the numbers cited across these lessons.
Retatrutide for Obesity (Phase 3)
Eli Lilly · May 2026 · ~28.3% weight loss at 12 mg over 80 weeks
Lilly Press Release →Triple Hormone-Receptor Agonist Retatrutide for Obesity
Rosenstock et al. · N Engl J Med 2023 · NCT04881760
NEJM →All retatrutide Phase 3 trials
Multiple ongoing trials · Eli Lilly · check registry for latest status
ClinicalTrials.gov →
Metabolic optimization compounds, ready when you are.
- 99%+ purity on every compound
- Batch-matched COAs included
- Discreet, same-day shipping
- Metabolic optimization compounds from $70
- 24/7 research support team
- GLP research compounds
- US-based peptide vendor
- Lab supplies included